Both nonselective and selective β-blockers should be avoided in patients with asthma, unless there are compelling reasons for their use. Care should be taken while co-administering of CYP3A4 inhibitors (ie, ketoconazole, ritonavir) and salmeterol-fluticasone as there is an increased risk of systemic side effects of individual component.